Agile Therapeutics Company Profile (NASDAQ:AGRX)

Analyst Ratings

Consensus Ratings for Agile Therapeutics (NASDAQ:AGRX) (?)
Ratings Breakdown: 5 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $16.60 (144.84% upside)

Analysts' Ratings History for Agile Therapeutics (NASDAQ:AGRX)
Show:
DateFirmActionRatingPrice TargetActions
7/8/2016Noble FinancialReiterated RatingBuy$15.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/17/2016FBR & CoReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/31/2016Cantor FitzgeraldReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/2/2016Royal Bank Of CanadaReiterated RatingOutperform$13.00 -> $15.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/10/2015William BlairReiterated RatingBuy$18.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/30/2014Sterne Agee CRTInitiated CoverageBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/29/2014 forward)

Earnings

Earnings History for Agile Therapeutics (NASDAQ:AGRX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/11/2016        
5/9/2016Q1($0.38)($0.27)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/13/2015($0.37)($0.38)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/12/2015($0.35)($0.35)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/26/2015($0.40)($0.37)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/13/2014($0.50)($0.34)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Agile Therapeutics (NASDAQ:AGRX)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163($0.46)($0.30)($0.38)
Q2 20162($0.29)($0.27)($0.28)
Q3 20162($0.28)($0.24)($0.26)
Q4 20162($0.24)($0.13)($0.19)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Agile Therapeutics (NASDAQ:AGRX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Agile Therapeutics (NASDAQ:AGRX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
1/27/2016Jay MoorinMajor ShareholderBuy393,700$6.35$2,499,995.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/2/2015Alfred AltomariCEOBuy2,500$8.73$21,825.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/23/2015Jay MoorinMajor ShareholderBuy811,966$5.85$4,750,001.10View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/29/2014Care Capital Iii LlcMajor ShareholderBuy500,000$6.00$3,000,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/23/2014Andrew N SchiffDirectorBuy1,333,333$6.00$7,999,998.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/22/2014Ab InvestorMajor ShareholderBuy1,000,000$6.00$6,000,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Agile Therapeutics (NASDAQ:AGRX)
DateHeadline
07/28/16 03:18 PMAgile Therapeutics Appoints Seth H. Z. Fischer to its Board of Directors - [at noodls] - PRINCETON, N.J., July 28, 2016 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (Nasdaq:AGRX) today announced the appointment of Seth H. Z. Fischer to the Company's Board of Directors, effective July 28, ...
07/21/16 07:42 AMWhy Agile Therapeutics (AGRX) Stock Might be a Great Pick -
07/13/16 10:26 AMSAGE On A High, JUNO Rockets As FDA Lifts Clinical Hold, FDA Panel Nod For AMGN
07/13/16 07:32 AMAGILE THERAPEUTICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits -
07/12/16 03:23 PMAgile Therapeutics Announces Plans to Advance Contraceptive Pipeline - [at noodls] - PRINCETON, N.J., July 12, 2016 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a women's health specialty pharmaceutical company focused on the development and commercialization of new prescription ...
07/06/16 03:32 PMAGILE THERAPEUTICS INC Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financial Stateme -
07/06/16 03:31 PMAgile Therapeutics Strengthens Executive Leadership Team with New Chief Commercial Officer - [at noodls] - PRINCETON, N.J., July 06, 2016 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (NASDAQ:AGRX), a women's health specialty pharmaceutical company focused on the development and commercialization of new prescription ...
06/24/16 02:21 PMAgile Therapeutics : to Present at the Cantor Fitzgeralds 2nd Annual Healthcare Conference
06/23/16 03:19 PMAgile Therapeutics to Present at the Cantor Fitzgerald's 2nd Annual Healthcare Conference - [at noodls] - PRINCETON, N.J., June 23, 2016 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX) a women's health specialty pharmaceutical company focused on the development and commercialization of new prescription ...
06/23/16 03:10 PMAgile Therapeutics to Present at the Cantor Fitzgerald’s 2nd Annual Healthcare Conference - [GlobeNewswire] - PRINCETON, N.J., June 23, 2016-- Agile Therapeutics, Inc. a women’ s health specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products, ...
06/16/16 07:00 AM8:00 am Agile Therapeutics issued patent that includes claims covering the formulation of a progestin-only transdermal patch containing levonorgestrel and is expected to expire in 2032 -
06/16/16 07:00 AMAgile Therapeutics Announces Issuance of Patent for Progestin Patch Designs - [GlobeNewswire] - PRINCETON, N.J., June 16, 2016-- Agile Therapeutics, Inc.,, a women's health specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products, ...
06/08/16 03:17 PMAGILE THERAPEUTICS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
06/07/16 07:18 AMAgile Therapeutics to Present at the William Blair & Company's 36th Annual Growth Stock Conference - [at noodls] - PRINCETON, N.J., June 07, 2016 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX) a women's health specialty pharmaceutical company focused on the development and commercialization of new prescription ...
06/07/16 07:00 AMAgile Therapeutics to Present at the William Blair & Company’s 36th Annual Growth Stock Conference - [GlobeNewswire] - PRINCETON, N.J., June 07, 2016-- Agile Therapeutics, Inc. a women’ s health specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products ...
06/06/16 01:26 PMAgile Therapeutics, Inc. :AGRX-US: Earnings Analysis: Q1, 2016 By the Numbers : June 6, 2016 -
05/31/16 04:44 PMThese Billionaires Just Made a Killing on Celator. Here's What Else They've Been Buying -
05/31/16 07:52 AMCan Agile Therapeutics (AGRX) Run Higher on Strong Earnings Estimate Revisions? -
05/30/16 05:21 PMAgile Therapeutics (AGRX) – Investment Analysts' Weekly Ratings Updates - Let Me Know About This - Agile Therapeutics (AGRX) – Investment Analysts' Weekly Ratings UpdatesLet Me Know About ThisAgile Therapeutics Inc (NASDAQ:AGRX) opened at 7.98 on Monday. The company's 50-day moving average price is $6.39 and its 200 day moving average price is $6.92. Agile Therapeutics Inc has a 12 month low of $5.32 and a 12 month high of $11.30.
05/29/16 10:15 PMStock Rating Review for Agile Therapeutics, Inc. (NASDAQ:AGRX) - HNN - Stock Rating Review for Agile Therapeutics, Inc. (NASDAQ:AGRX)HNNInvestors may choose to follow the views of professional Wall Street analysts that regularly track the company. Covering equity analysts presently have a consensus stock rating of 1 on shares of Agile Therapeutics, Inc. (NASDAQ:AGRX). Covering analysts ...
05/28/16 05:13 PMCaxton Corp Increased Agile Therapeutics INC (NASDAQ:AGRX) by $8.44 Million as Shares Declined - CCH Daily News - Caxton Corp Increased Agile Therapeutics INC (NASDAQ:AGRX) by $8.44 Million as Shares DeclinedCCH Daily NewsCaxton Corp increased its stake in Agile Therapeutics Inc (NASDAQ:AGRX) by 6103.04% based on its latest 2016Q1 regulatory filing with the SEC. Caxton Corp bought 1.41M shares as the company's stock declined 34.29% while stock markets rallied.Agile Therapeutics, Inc. (NASDAQ:AGRX) Impact Score At 0Enterprise Leaderall 2 news articles »
05/25/16 08:32 AMFast Moving Stocks: Agile Therapeutics, (NASDAQ:AGRX), Oracle (NYSE:ORCL), bluebird bio, (NASDAQ:BLUE ... - KC Register - Fast Moving Stocks: Agile Therapeutics, (NASDAQ:AGRX), Oracle (NYSE:ORCL), bluebird bio, (NASDAQ:BLUE ...KC RegisterAgile Therapeutics, Inc. (NASDAQ:AGRX) reported financial results for the three months ended March 31, 2016 and provided a corporate update for the first quarter 2016. Net loss was $7.3 million, or $0.27 per basic share for the quarter ended March 31, ...
05/25/16 08:32 AMEarnings Review and Stock Rundown for Agile Therapeutics, Inc. (NASDAQ:AGRX) - Wall Street Hints and News - Earnings Review and Stock Rundown for Agile Therapeutics, Inc. (NASDAQ:AGRX)Wall Street Hints and NewsInvestors and analysts will be paying close attention when the company posts earnings results. Earnings numbers can provide insight into a company's overall profitability. Covering equity analysts are expecting Agile Therapeutics, Inc. (NASDAQ:AGRX) to ...and more »
05/24/16 05:23 PMTarget Check and Stock Performance Recap Agile Therapeutics, Inc. (NASDAQ:AGRX) - Wall Street Hints and News - Target Check and Stock Performance Recap Agile Therapeutics, Inc. (NASDAQ:AGRX)Wall Street Hints and NewsTracking stock performance from various views may help with share evaluation. Some investors might be more focused on short-term share action while others may prefer to view long-term performance. In recent session activity, Agile Therapeutics, Inc.and more »
05/22/16 09:51 PMStock Rating Review for Agile Therapeutics, Inc. (NASDAQ:AGRX) - Wall Street Hints and News - Stock Rating Review for Agile Therapeutics, Inc. (NASDAQ:AGRX)Wall Street Hints and NewsInvestors may choose to follow the views of professional Wall Street analysts that regularly track the company. Covering equity analysts presently have a consensus stock rating of 1 on shares of Agile Therapeutics, Inc. (NASDAQ:AGRX). Covering analysts ...and more »
05/20/16 08:50 AMLatest Analyst Ratings For Agile Therapeutics, Inc. (AGRX) - Share Trading News - Latest Analyst Ratings For Agile Therapeutics, Inc. (AGRX)Share Trading News02/02/2016 – Agile Therapeutics, Inc. had its “outperform” rating reiterated by analysts at RBC Capital. They now have a USD 15 price target on the stock. 01/08/2016 – Cantor Fitzgerald began new coverage on Agile Therapeutics, Inc. giving the company ...and more »
05/18/16 05:17 PMShare Recap and Earnings Focus on Agile Therapeutics, Inc. (NASDAQ:AGRX) - Wall Street Hints and News - Share Recap and Earnings Focus on Agile Therapeutics, Inc. (NASDAQ:AGRX)Wall Street Hints and NewsAnalysts and investors are usually very focused on company earnings numbers when they are released. Company earnings are a good way to evaluate the profitability of the company. Presently, covering analysts are anticipating Agile Therapeutics, Inc.and more »
05/17/16 10:15 PMShare Performance and Target Price Review for Agile Therapeutics, Inc. (NASDAQ:AGRX) - Wall Street Hints and News - Share Performance and Target Price Review for Agile Therapeutics, Inc. (NASDAQ:AGRX)Wall Street Hints and NewsLooking at stock activity from multiple angles may be of benefit when examining share performance. Investors have the ability to focus in on short or long term share performance. During the most recent trading session, Agile Therapeutics, Inc.and more »
05/17/16 12:04 PMAGILE THERAPEUTICS INC Financials -
05/16/16 05:02 PMConsensus Rating Review for Agile Therapeutics, Inc. (NASDAQ:AGRX) - Wall Street Hints and News - Consensus Rating Review for Agile Therapeutics, Inc. (NASDAQ:AGRX)Wall Street Hints and NewsEquity research analysts currently have a consensus rating of 1 on shares of Agile Therapeutics, Inc. (NASDAQ:AGRX). Sell-side analysts will typically rate a company's stock based on extensive research. These ratings usually translate into a Buy, Sell, ...and more »
05/12/16 05:38 PMMorning Watch List:Agile Therapeutics, Inc. (NASDAQ:AGRX), Winthrop Realty Trust (NYSE:FUR), Facebook Inc ... - KC Register - Morning Watch List:Agile Therapeutics, Inc. (NASDAQ:AGRX), Winthrop Realty Trust (NYSE:FUR), Facebook Inc ...KC RegisterAgile Therapeutics, Inc. (NASDAQ:AGRX) reported financial results for the three months ended March 31, 2016 and provided a corporate update for the first quarter 2016. Net loss was $7.3 million, or $0.27 per basic share for the quarter ended March 31, ...and more »
05/11/16 03:50 AMAgile Therapeutics Inc (AGRX) Rating Reiterated by FBR & Co. - Washington News Wire - Washington News WireAgile Therapeutics Inc (AGRX) Rating Reiterated by FBR & Co.Washington News WireAgile Therapeutics Inc (NASDAQ:AGRX)'s stock had its “buy” rating reissued by equities research analysts at FBR & Co. in a note issued to investors on Tuesday, Marketbeat.com reports. Agile Therapeutics (NASDAQ:AGRX) opened at 6.22 on Tuesday.Agile Therapeutics Inc (AGRX) Posts Quarterly Earnings Results, Beats Estimates By $0.11 EPSNewsWay 21New Analyst Ratings On Agile Therapeutics, Inc. (AGRX)Risers & FallersAgile Therapeutics Inc (AGRX) Rating Increased to Buy at Zacks Investment ResearchWeb Breaking NewsMoney Morning -Analyst Ratings -The Wall Street Transcriptall 13 news articles »
05/10/16 03:47 AMPerformance Recap and Target Perspective on Agile Therapeutics, Inc. (NASDAQ:AGRX) - B.O.D.Y Confidential - Performance Recap and Target Perspective on Agile Therapeutics, Inc. (NASDAQ:AGRX)B.O.D.Y ConfidentialIn the latest trading session, shares of Agile Therapeutics, Inc. (NASDAQ:AGRX) moved +1.87%. In order to gain some further insight on stock performance, we can take a look at the stock price relative to some moving averages. After a recent check ...and more »
05/09/16 05:18 PMAgile Therapeutics reports 1Q loss -
05/09/16 03:28 PMAgile Therapeutics Reports First Quarter 2016 Financial Results - [at noodls] - Cash Expected to Fund Operations through the End of 2017 Clinical Trial Expected to Complete in Fourth Quarter 2016 and Resubmission Planned for First Half 2017 PRINCETON, N.J., May 09, 2016 (GLOBE NEWSWIRE) ...
05/09/16 06:07 AMQ1 2016 Agile Therapeutics Inc Earnings Release - After Market Close -
05/04/16 10:41 PMEarnings Outlook on Agile Therapeutics, Inc. (NASDAQ:AGRX) - B.O.D.Y Confidential - Earnings Outlook on Agile Therapeutics, Inc. (NASDAQ:AGRX)B.O.D.Y ConfidentialAnalysts and investors will be anticipating Agile Therapeutics, Inc. (NASDAQ:AGRX)'s next earnings release which is expected to be posted on or around 2016-05-10. Sell-side research firms on Wall Street are expecting that the company will post EPS of ...and more »
05/02/16 05:54 PMAverage Analyst Rating for Agile Therapeutics, Inc. (NASDAQ:AGRX) - B.O.D.Y Confidential - Average Analyst Rating for Agile Therapeutics, Inc. (NASDAQ:AGRX)B.O.D.Y ConfidentialWall Street analysts have provided an average broker recommendation of 1 on Agile Therapeutics, Inc. (NASDAQ:AGRX) shares. The rating is determined by using the average of all analyst recommendations taken into consideration by Zacks Research.and more »
04/26/16 05:57 PMShare Performance and Target Price Review Agile Therapeutics, Inc. (NASDAQ:AGRX) - B.O.D.Y Confidential - Share Performance and Target Price Review Agile Therapeutics, Inc. (NASDAQ:AGRX)B.O.D.Y ConfidentialDuring the most recent trading session, shares of Agile Therapeutics, Inc. (NASDAQ:AGRX) ended up with a move of -3.13%. Sell-side analysts have given a consensus target price of $16.20 on company shares. Target price projections may differ greatly ...and more »
04/24/16 11:21 PMBroker Roundup For Agile Therapeutics, Inc. (AGRX) - Share Trading News - Broker Roundup For Agile Therapeutics, Inc. (AGRX)Share Trading News09/16/2014 – Agile Therapeutics, Inc. had its “buy” rating reiterated by analysts at Janney Montgomery Scott. They now have a USD 18 price target on the stock. The share price of Agile Therapeutics, Inc. (AGRX) was down -2.09% during the last trading ...Agile Therapeutics, Inc. (NASDAQ:AGRX) Reported Basic Consolidated EPS Of $-1.3778Enterprise LeaderIt Seems Agile Therapeutics Inc Will Go Down. Have Another Big DeclineThe Postall 3 news articles »
04/22/16 05:52 PMAgile Therapeutics, Inc. (NASDAQ:AGRX) Share Rating Recap - The Post - Agile Therapeutics, Inc. (NASDAQ:AGRX) Share Rating RecapThe PostShares of Agile Therapeutics, Inc. (NASDAQ:AGRX) are tracked by analysts as well as crowd investors. Research from Beta Systems keeps track of crowd sourced sentiment and provides consensus stock ratings. The rating information comes mainly from ...and more »
04/22/16 05:52 PMAgile Therapeutics, Inc. (AGRX) Latest Broker Views - Risers & Fallers - Agile Therapeutics, Inc. (AGRX) Latest Broker ViewsRisers & FallersA number of investment brokers have recently updated their price targets on shares of Agile Therapeutics, Inc. (AGRX). According to the latest broker reports outstanding on Friday 22nd of April, 0 analysts have a rating of “strong buy”, 0 analysts “buy ...and more »
04/22/16 05:52 PMAnalysts Expect PXSG To Hit $28 - Three of PXSG's underlying holdings with notable upside to their analyst target prices are Agile Therapeutics Inc (AGRX), La Jolla Pharmaceutical Co. (LJPC), and Paratek Pharmaceuticals Inc (PRTK). Although AGRX has traded at a recent price of $6.70/share ...
03/30/16 03:21 PMAgile Therapeutics to Present at the 15th Annual Needham Healthcare Conference - [at noodls] - PRINCETON, N.J., March 30, 2016 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a women's health specialty pharmaceutical company focused on the development and commercialization of new prescription ...
03/09/16 04:09 PMAgile Therapeutics reports 4Q loss -
03/09/16 03:10 PMAgile Therapeutics Reports Fourth Quarter and Full Year 2015 Financial Results - [GlobeNewswire] - PRINCETON, N.J., March 09, 2016-- Agile Therapeutics, Inc., a women's health specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products, ...
03/03/16 03:15 PMAgile Therapeutics to Present at the 28th Annual ROTH Conference - [GlobeNewswire] - PRINCETON, N.J., March 03, 2016-- Agile Therapeutics, Inc. a women’ s health specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products, ...
02/24/16 03:22 PMAGILE THERAPEUTICS INC Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD Disclosure, Finan -
02/24/16 03:15 PMAgile Therapeutics Appoints Ajit S. Shetty, Ph.D., to Its Board of Directors - [GlobeNewswire] - PRINCETON, N.J., Feb. 24, 2016-- Agile Therapeutics, Inc., today announced that Ajit S. Shetty, Ph.D., has been appointed to the Company's Board of Directors, effective February 24, 2016. Dr. Shetty will ...
02/16/16 03:15 PMAgile Therapeutics to Present at the 2016 RBC Capital Markets’ Global Healthcare Conference - [GlobeNewswire] - PRINCETON, N.J., Feb. 16, 2016-- Agile Therapeutics, Inc. a women’ s health specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products, ...

Social

About Agile Therapeutics

Agile Therapeutics logoAgile Therapeutics, Inc. is a women's health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company's lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch. In addition to Twirla, the Company is developing a pipeline of other new transdermal contraceptive products, including AG200-ER, which is a regimen designed to allow a woman to extend the length of her cycle; AG200-SP, which is a regimen designed to provide a shortened hormone-free interval, and AG890, which is a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Each of its product candidates utilizes its Skinfusion technology designed to deliver contraceptive-levels of hormones to the blood stream through the skin over a seven-day period.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drugs - Generic
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: AGRX
  • CUSIP:
Key Metrics:
  • Previous Close: $6.78
  • 50 Day Moving Average: $7.22
  • 200 Day Moving Average: $6.64
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $194.87M
  • Beta: 2.88
  • Current Year EPS Consensus Estimate: $-1.06 EPS
  • Next Year EPS Consensus Estimate: $-0.99 EPS
Additional Links:
Agile Therapeutics (NASDAQ:AGRX) Chart for Friday, July, 29, 2016